We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Dips While Market Gains: Key Facts
Read MoreHide Full Article
In the latest trading session, Ginkgo Bioworks Holdings, Inc. (DNA - Free Report) closed at $12.74, marking a -4.85% move from the previous day. This change lagged the S&P 500's daily gain of 0.23%. Meanwhile, the Dow experienced a rise of 0.34%, and the technology-dominated Nasdaq saw an increase of 0.8%.
The company's stock has climbed by 1.21% in the past month, falling short of the Medical sector's gain of 5.57% and the S&P 500's gain of 3.57%.
Market participants will be closely following the financial results of Ginkgo Bioworks Holdings, Inc. in its upcoming release. The company's upcoming EPS is projected at -$1.24, signifying a 14.81% drop compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $39 million, down 56.2% from the year-ago period.
DNA's full-year Zacks Consensus Estimates are calling for earnings of -$5.27 per share and revenue of $181 million. These results would represent year-over-year changes of +49.13% and -20.28%, respectively.
It is also important to note the recent changes to analyst estimates for Ginkgo Bioworks Holdings, Inc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Currently, Ginkgo Bioworks Holdings, Inc. is carrying a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 89, which puts it in the top 37% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Dips While Market Gains: Key Facts
In the latest trading session, Ginkgo Bioworks Holdings, Inc. (DNA - Free Report) closed at $12.74, marking a -4.85% move from the previous day. This change lagged the S&P 500's daily gain of 0.23%. Meanwhile, the Dow experienced a rise of 0.34%, and the technology-dominated Nasdaq saw an increase of 0.8%.
The company's stock has climbed by 1.21% in the past month, falling short of the Medical sector's gain of 5.57% and the S&P 500's gain of 3.57%.
Market participants will be closely following the financial results of Ginkgo Bioworks Holdings, Inc. in its upcoming release. The company's upcoming EPS is projected at -$1.24, signifying a 14.81% drop compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $39 million, down 56.2% from the year-ago period.
DNA's full-year Zacks Consensus Estimates are calling for earnings of -$5.27 per share and revenue of $181 million. These results would represent year-over-year changes of +49.13% and -20.28%, respectively.
It is also important to note the recent changes to analyst estimates for Ginkgo Bioworks Holdings, Inc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Currently, Ginkgo Bioworks Holdings, Inc. is carrying a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 89, which puts it in the top 37% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.